№ files_lp_4_process_2_52553
File format: docx
Character count: 729
File size: 1788 KB
This document is an announcement informing customers about the discontinuation of a product and the introduction of its replacement, highlighting key differences.
Year:
2025
Region / City:
N/A
Subject:
Product discontinuation, replacement product
Document Type:
Announcement
Organization / Institution:
AccuTec, Inc.
Author:
Garnett A. Andes
Target Audience:
Existing customers
Effective Date:
January 20, 2025
Date of Change:
January 20, 2025
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Topic:
Program Discontinuation
Document Type:
Form
Organization / Institution:
ACCSC
Target Audience:
Educational institutions
Year:
2026
Region / City:
United Kingdom
Theme:
Pharmaceutical Treatment
Document Type:
Prescribing Information
Organization:
NHS
Author:
Dr. Joanne Ritchie
Target Audience:
Healthcare professionals, specifically specialists and GPs
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Contraindications:
Venous thromboembolic disorder, arterial thromboembolic disease, known thrombophilic disorders, known osteoporosis, headaches with focal neurological symptoms, pregnancy, breastfeeding
Monitoring:
DEXA scan recommended after 1 year of treatment
Special Warnings/Precautions:
Use of non-hormonal contraception for at least 1 month after initiation
Adverse Effects:
Hot flushes, headache
Primary Care responsibilities for continuation:
Prescribe as recommended, seek advice from the specialist if needed
Specialist Service responsibilities for initiation:
Discuss benefits and side effects with the patient, initiate treatment and monitor
Criteria for Discontinuation:
Menopause, increase in migraine frequency, ATE/VTE events, acute liver deterioration
Date of Initiation:
Not specified
Communication:
Contact details for the specialist and hospital pharmacy provided
Note:
Year
Subject:
Discontinuation of Appointment
Document Type:
Notice
Organization / Institution:
Washington State University
Target Audience:
Employee
Year:
2017
Region / City:
Pullman, Washington
Subject:
Employment termination
Document Type:
Notification
Organization / Institution:
Washington State University
Author:
Appointing Authority
Target Audience:
Employee of Washington State University
Effective Period:
April 3, 2017
Approval Date:
April 3, 2017
Amendment Date:
None
Year:
2024
Note:
Region / City
Theme:
Product Discontinuation
Document Type:
Notice
Organization / Institution:
Honeywell
Author:
Honeywell Intelligrated
Period of Validity:
2024-2025
Final Order Date:
6-09-2025
Discontinuation Date:
8-09-2025
Date:
May 15, 2024
Company:
Honeywell Intelligrated
Legal Entity:
Intelligrated Systems, LLC
Product Name:
Mathews SWD (Swivel Wheel Divert)
Subject:
Discontinuation of product line and last time buy notice
Discontinuation Date:
August 23, 2025
Final Order Date (Last Time Buy):
June 23, 2025
Reason for Discontinuation:
Supply chain and component obsolescence constraints
Replacement Product:
Intelligrated Wheel Divert 2.0
Affected Materials:
Multiple part numbers listed in Mathews SWD Table 1.pdf
Order Conditions:
Non-cancellable and non-returnable LTB orders; first come, first served basis
Warranty Terms:
No warranty replacement parts available after discontinuation
Support Termination:
All parts and service support cease on August 23, 2025
Contact Information:
Parts Hotline 877.315.3400 (Option 2); [email protected]
Intended Audience:
Customers and purchasers of Mathews SWD products
Year:
2023
Region / City:
United States
Subject:
Healthcare, Pharmaceutical, Respiratory Care
Document Type:
Notification, Regulatory Update
Organization:
GlaxoSmithKline (GSK), U.S. Food and Drug Administration (FDA), MassHealth
Author:
GlaxoSmithKline (GSK), MassHealth
Target Audience:
Healthcare providers, MassHealth members, Pharmacists
Effective Date:
December 31, 2023 (discontinuation), December 4, 2023 (PA changes)
Date of Approval:
June 2, 2023
Date of Changes:
September 29, 2023
Year:
2019
Region / City:
United States
Topic:
Affordable Care Act, Health Insurance
Document Type:
Regulatory Guidance
Agency / Institution:
U.S. Department of Health and Human Services
Author:
Centers for Medicare & Medicaid Services
Target Audience:
Health Insurance Issuers, Exchanges, Consumers
Effective Period:
2019 and Beyond
Approval Date:
July 6, 2018
Modification Date:
July 30, 2019
Document type:
Administrative form
Subject:
Course discontinuation and withdrawal from delivery
Institutional context:
Higher education
Responsible unit:
Quality team
Institutional body for approval:
Portfolio Oversight Committee
Institutional authority supporting proposal:
Dean of School / Head of Higher Education
Fields included:
Course name and award; School or Partner Institution; Course Leader; Validation period; Rationale for discontinuation; Student numbers; Student consultation; Exit strategy; Closure timeline; Applicant actions; Implications for other courses; Staffing implications
Student data scope:
Previous three academic years including headcount and FTE for part-time students
Academic levels referenced:
Level 3; Level 4; Level 5; Level 6; Level 7
Submission requirement:
Form submitted to Quality team for allocation of form number at least 10 working days before committee consideration
Approval process:
Signature and date by School authority and Portfolio Oversight Committee
Purpose:
Formal proposal and review process for permanent withdrawal of an academic course
Year:
2013
Region / City:
N/A
Topic:
Program Discontinuation
Document Type:
Proposal
Institution:
School of Business and Technology
Author:
Andrew Blitz
Target Audience:
Faculty, Academic Affairs
Action Period:
Fall 2014
Approval Date:
12/31/2013
Change Date:
02/18/2014
Country:
United States
State:
Illinois
City:
Chicago
Subject:
Discontinuation of a hospital facility
Document type:
Legal notice of public hearing
Related legislation:
Illinois Health Facilities Planning Act
Regulatory reference:
77 Illinois Administrative Code Part 1130
Responsible body:
Illinois Health Facilities and Services Review Board
Project number:
25-002
Healthcare facility:
Advocate Trinity Hospital
Facility address:
2320 East 93rd Street, Chicago, Illinois
Public hearing date:
April 7, 2025
Public hearing time:
1:00 PM
Hearing location:
Compassion Baptist Church, 2650 E 95th St, Chicago, IL 60617
Participation format:
Public hearing with written and verbal comments
Submission requirements:
Two copies of supporting documentation on 8½ × 11 inch paper
Contact person:
John P. Kniery
Contact phone:
(217) 782-3516
TTY contact:
800-547-0466
Accessibility notice:
Meeting accessible to persons with special needs upon prior notification
Year:
2023
Region / City:
Not specified
Topic:
Biologic persistence analysis
Document Type:
Research Supplement
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Researchers, Healthcare Professionals
Period of Effect:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2026
Region / City:
Not specified
Topic:
Pediatric endocrinology, growth hormone therapy
Document Type:
Clinical trial information letter
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Parents and guardians of children with isolated growth hormone deficiency
Study Type:
Non-inferiority randomized controlled trial
Purpose:
To evaluate the final height outcomes in children with I-GHD after discontinuation vs continuation of GH therapy
Participation:
Voluntary
Method:
GH stimulation test
Year:
2025
Region / City:
Washington, D.C.
Topic:
Drug Development, Clinical Trials, Sickle Cell Disease
Document Type:
Press Release
Organization / Institution:
Sickle Cell Medical Advocacy Inc., Sickle Cell Foundation of Georgia, Inc., Sickle Cell Disease Association of America Inc., Crescent Foundation, SC RED, Sickle Cell 101, Sickle Cell Community Consortium
Author:
Sickle Cell Advocates
Target Audience:
Sickle Cell Disease Community, Medical Researchers, Pharmaceutical Industry
Effective Period:
August 15, 2025
Approval Date:
August 15, 2025
Date of Changes:
N/A
Note:
Contextual Description
Date:
[Date]
Country:
United States
State:
Washington
Topic:
Health insurance coverage and plan enrollment
Document type:
Notice letter
Issuing organization:
Washington Healthplanfinder (Washington Health Benefit Exchange) and participating health plan issuer
Recipient:
Policyholder and enrolled household members
Subject:
Termination of current health plan and selection of replacement coverage
Current coverage end date:
December 31, [insert current year]
Open enrollment period:
November 1 – December 15, [insert current year]
Additional plan selection period:
December 16, [insert current year] – January 15, [insert upcoming year]
New coverage start dates:
January 1, [insert upcoming year] or February 1, [insert upcoming year] depending on enrollment date
Related programs:
Cascade Care Savings Program, Premium Tax Credits
Contact platform:
Washington Healthplanfinder (www.wahealthplanfinder.org
Note:
)